New tool PISA-REX facilitates drug development

Researchers have developed an industry-standard tool to facilitate drug development and translational research in collaboration between labs at Karolinska Institutet and the Gygi Lab at Harvard Medical School. Their results are published in Advanced Science.

Redox signaling is important in many cellular processes and dysregulation of redox signaling pathways can be involved in the pathobiology of disease. In this collaboration, the labs at Karolinska Institutet and Harvard Medical School developed a novel high-depth and high-throughput redox proteomics approach (REX) to study redox signaling in cells and tissues.

The labs also integrated REX with proteome-wide solubility and expression analysis in a robust tool, PISA-REX, to help understand the drug mechanism of action and disease pathobiology.

“By understanding drug mechanism of action and revealing disease mechanisms, PISA-REX can facilitate drug development and translational research,” says Amir Ata Saei, co-author and Assistant Professor at the Department of Microbiology, Tumor and Cell Biology at Karolinska Institutet.

“Developing this industry-standard tool, we aim to extend the applications of PISA-REX to other exciting model systems involving host-pathogen interactions, drug/antibiotic resistance, and cancer,” says Roman Zubarev, co-author and Professor at the Department of Medical Biochemistry and Biophysics at Karolinska Institutet.